Key Takeaway: Precision BioSciences has reported initial safety and antiviral activity results for PBGENE-HBV in the ELIMINATE-B Phase 1 clinical trial. The trial is progressing as planned, with the first dose administered to three patients in cohort 1. The gene editing technology was found to be safe and well tolerated, showing promising antiviral effects against chronic Hepatitis B.
Price reaction · baseline $5.15 (2025-02-18 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
+9.7%
day 1 · peak
+14.4%
day 3
+9.3%
Market Sentiment Analysis
POSITIVE FACTORS
PBGENE-HBV was safe and well tolerated in the initial study.
The trial is executing on schedule.
Substantial antiviral activity was demonstrated.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing technology studied for Hepatitis B, was safe and well tolerated PBGENE-HBV demonstrated substantial
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is the first LNP gene editing technology studied for chronic Hepatitis B.
What phase is the ELIMINATE-B trial?
The ELIMINATE-B trial is a Phase 1 dose finding study.
How many patients were in cohort 1?
Cohort 1 consisted of 3 patients.
Was PBGENE-HBV well tolerated?
Yes, PBGENE-HBV was reported as safe and well tolerated.
What were the results of the trial?
The trial demonstrated substantial antiviral activity against Hepatitis B.